BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1403@pharmaconomics
DTSTAMP:20260707T051101Z
DTSTART;VALUE=DATE:20250217
DTEND;VALUE=DATE:20250218
SUMMARY:HCM Phase 3 — fruquintinib
DESCRIPTION:Phase 3 trial results for fruquintinib in renal cell carcinoma are due Feb 17\, 2025. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1648257/000164825726000033/hcm-20260521xex99d1.htm\n\nTrack it: https://www.pharmaconomics.com/e/1403
URL:https://www.pharmaconomics.com/e/1403
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:HCM catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR